CD274 and non-small cell lung carcinoma: Since then, almost all clinical studies of immune-checkpoint inhibitors in NSCLC investigated the potential correlation between tumor PD-L1 expression and anti-PD-1/PD-L1 MoAbs activity/efficacy [19-24, 26-30], in order to validate PD-L1 expression as predictive biomarker.